Compare Amgen, Inc. (AMGN) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Union Pacific Corporation — how do they compare? Amgen, Inc. trades at $357.3 (market cap $196.12B), while Union Pacific Corporation trades at $289.34 (market cap $170.37B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | UNP | |
|---|---|---|
Market Cap | $196.12B | $170.37B |
Sector | Health | Industrials |
52-Week High | $388.16 | $286.96 |
52-Week Low | $271.18 | $214.91 |
Enterprise Value | $241.41B | $200.84B |
Dividend Yield | 2.77% | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Union Pacific (UNP) trades at $286.96, up 0.67% today, with strong technical momentum indicated by bullish moving averages. The company maintains robust fundamentals with a 29.2% net income margin and consistent earnings beats in recent quarters. Key developments include the proposed $85 billion merger with Norfolk Southern, though regulatory scrutiny remains. Cash flow from operations remains healthy at $9.29 billion for 2025, supporting dividend payments and strategic initiatives.
Outlook remains positive with analyst consensus targeting $296.27, though risks include merger approval uncertainties and a class-action lawsuit. The stock's current valuation at 23.62 P/E reflects premium pricing, requiring sustained earnings growth to justify further upside. Near-term focus is on Q2 2026 earnings release scheduled for July 23, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
